Moderna said on Friday it is cancelling plans to build a messenger RNA manufacturing plant in Japan due to "changes in the ...

A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector.

In the most recent trading session, Moderna (MRNA) closed at $31.25, indicating a -2.95% shift from the previous trading day.

The two companies collaborated on research showing quantum computing could greatly aid the design of mRNA-based medicines and ...

Moderna (MRNA) stock in focus as the company cancels plans for an mRNA manufacturing plant in Japan amid a challenging ...

Moderna, already in cash-saving mode amid uncertain vaccine dynamics, is backing off from its plans to construct an mRNA drug ...

In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

Moderna Japan had planned to build an mRNA drug plant at Shonan Health Innovation Park in Kanagawa prefecture. The company shelved the plan, citing weak demand for vaccines and a poor business ...

This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...

Moderna’s COVID-19 vaccine has received full FDA approval for use in children at higher risk for severe illness.

El Parlamento cubano aprobó el viernes una nueva Ley del Registro Civil que permite a las personas cambiar su género en sus ...

The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.